Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082663 | 0.84 | TRPV1 (0.56) | TRPV1HDAC1RXFP1NPC1RAB9A | |
| SCHEMBL14082381 | 0.84 | HDAC1 (0.53) | TRPV1HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL14082678 | 0.84 | TRPV1 (0.55) | TRPV1HDAC1RXFP1NPC1RAB9A | |
| SCHEMBL14108040 | 0.84 | PTGS1 (0.67) | TRPV1HDAC1HDAC2PTGS1 | |
| SCHEMBL14082209 | 0.82 | HDAC1 (0.61) | TRPV1HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL14082673 | 0.81 | MLYCD (0.58) | TRPV1NPC1RAB9AKMT2A | |
| SCHEMBL14082629 | 0.81 | TRPV1 (0.70) | TRPV1NPC1RAB9A | |
| SCHEMBL14082710 | 0.81 | RAB9A (0.58) | TRPV1HDAC1RXFP1NPC1RAB9A | |
| SCHEMBL14082694 | 0.80 | RXFP1 (0.56) | TRPV1RXFP1KMT2A | |
| SCHEMBL14082648 | 0.80 | PHGDH (0.53) | TRPV1HDAC1RXFP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885HDAC1 556/4885RXFP1 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.